WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018037306) FORMULATION FOR INHIBITING FORMATION OF 5-HT 2B AGONISTS AND METHODS OF USING SAME
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/037306    International Application No.:    PCT/IB2017/054740
Publication Date: 01.03.2018 International Filing Date: 02.08.2017
IPC:
A61K 45/06 (2006.01), A61K 31/05 (2006.01), A61K 31/137 (2006.01), A61K 31/36 (2006.01), A61K 31/551 (2006.01), A61P 3/04 (2006.01), A61P 25/08 (2006.01)
Applicants: ZOGENIX INTERNATIONAL LIMITED [GB/GB]; Siena Court Broadway Maidenhead Berkshire SL6 1NJ (GB)
Inventors: FARR, Stephen J.; (US).
BOYD, Brooks; (US)
Agent: CLARK, Andrew Peter; J A Kemp 14 South Square Gray's Inn London WC1R 5JJ (GB)
Priority Data:
62/379,183 24.08.2016 US
62/515,383 05.06.2017 US
Title (EN) FORMULATION FOR INHIBITING FORMATION OF 5-HT 2B AGONISTS AND METHODS OF USING SAME
(FR) FORMULATION POUR L'INHIBITION D'AGONISTES DE 5-HT2B ET PROCÉDÉS POUR LEUR UTILISATION
Abstract: front page image
(EN)Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
(FR)L'invention concerne des combinaisons de médicaments et leur utilisation. Un premier médicament est administré en combinaison avec un deuxième médicament. Le premier médicament, tel que la fenfluramine, est caractérisé par la formation d'un métabolite comprenant des agonistes de 5-HT2B tels que la norfenfluramine présentant des effets secondaires indésirables connus. Le deuxième médicament se présente sous la forme d'un inhibiteur de CYP tel que le cannabidiol qui module la formation de métabolite vers le bas, rendant ainsi le premier médicament plus sûr.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)